Better Therapeutics, Inc. (NASDAQ:BTTX – Get Rating) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 122,800 shares, an increase of 20.6% from the November 30th total of 101,800 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average trading volume of 41,800 shares, the short-interest ratio is presently 2.9 days.
Wall Street Analyst Weigh In
Separately, Chardan Capital dropped their price target on Better Therapeutics from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, November 15th.
Get
Better Therapeutics alerts:
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Better Therapeutics stock. Vanguard Group Inc. lifted its holdings in Better Therapeutics, Inc. (NASDAQ:BTTX – Get Rating) by 30.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 434,644 shares of the company's stock after purchasing an additional 101,098 shares during the quarter. Vanguard Group Inc. owned 1.83% of Better Therapeutics worth $765,000 as of its most recent filing with the SEC. Institutional investors own 7.46% of the company's stock.
Better Therapeutics Price Performance
Shares of NASDAQ BTTX opened at $1.11 on Friday. Better Therapeutics has a 1-year low of $0.91 and a 1-year high of $5.14. The company has a debt-to-equity ratio of 1.61, a current ratio of 2.52 and a quick ratio of 2.52. The business's fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.65. The firm has a market capitalization of $26.23 million, a PE ratio of -0.55 and a beta of 1.36.
Better Therapeutics (NASDAQ:BTTX – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. On average, research analysts expect that Better Therapeutics will post -1.81 EPS for the current year.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc, a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.
See Also
- Get a free copy of the StockNews.com research report on Better Therapeutics (BTTX)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
